Hansa Biopharma (Sweden) Probability of Future Stock Price Finishing Over 36.36
| HNSA Stock | SEK 30.68 0.80 2.68% |
Hansa |
Hansa Biopharma Target Price Odds to finish over 36.36
The tendency of Hansa Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over kr 36.36 or more in 90 days |
| 30.68 | 90 days | 36.36 | about 74.88 |
Based on a normal probability distribution, the odds of Hansa Biopharma to move over kr 36.36 or more in 90 days from now is about 74.88 (This Hansa Biopharma AB probability density function shows the probability of Hansa Stock to fall within a particular range of prices over 90 days) . Probability of Hansa Biopharma AB price to stay between its current price of kr 30.68 and kr 36.36 at the end of the 90-day period is about 19.09 .
Assuming the 90 days trading horizon Hansa Biopharma AB has a beta of -0.0938. This usually indicates as returns on the benchmark increase, returns on holding Hansa Biopharma are expected to decrease at a much lower rate. During a bear market, however, Hansa Biopharma AB is likely to outperform the market. Additionally Hansa Biopharma AB has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Hansa Biopharma Price Density |
| Price |
Predictive Modules for Hansa Biopharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Hansa Biopharma AB. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Hansa Biopharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Hansa Biopharma is not an exception. The market had few large corrections towards the Hansa Biopharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Hansa Biopharma AB, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Hansa Biopharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.76 | |
β | Beta against Dow Jones | -0.09 | |
σ | Overall volatility | 6.44 | |
Ir | Information ratio | -0.25 |
Hansa Biopharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Hansa Biopharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Hansa Biopharma AB can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Hansa Biopharma AB generated a negative expected return over the last 90 days | |
| Hansa Biopharma AB has high historical volatility and very poor performance | |
| Hansa Biopharma AB has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 154.53 M. Net Loss for the year was (609.57 M) with profit before overhead, payroll, taxes, and interest of 116.05 M. | |
| Hansa Biopharma AB has accumulated about 762.73 M in cash with (504.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 19.06. |
Hansa Biopharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Hansa Stock often depends not only on the future outlook of the current and potential Hansa Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Hansa Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 52.4 M | |
| Cash And Short Term Investments | 1.5 B |
Hansa Biopharma Technical Analysis
Hansa Biopharma's future price can be derived by breaking down and analyzing its technical indicators over time. Hansa Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Hansa Biopharma AB. In general, you should focus on analyzing Hansa Stock price patterns and their correlations with different microeconomic environments and drivers.
Hansa Biopharma Predictive Forecast Models
Hansa Biopharma's time-series forecasting models is one of many Hansa Biopharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Hansa Biopharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Hansa Biopharma AB
Checking the ongoing alerts about Hansa Biopharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Hansa Biopharma AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Hansa Biopharma AB generated a negative expected return over the last 90 days | |
| Hansa Biopharma AB has high historical volatility and very poor performance | |
| Hansa Biopharma AB has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 154.53 M. Net Loss for the year was (609.57 M) with profit before overhead, payroll, taxes, and interest of 116.05 M. | |
| Hansa Biopharma AB has accumulated about 762.73 M in cash with (504.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 19.06. |
Additional Tools for Hansa Stock Analysis
When running Hansa Biopharma's price analysis, check to measure Hansa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hansa Biopharma is operating at the current time. Most of Hansa Biopharma's value examination focuses on studying past and present price action to predict the probability of Hansa Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hansa Biopharma's price. Additionally, you may evaluate how the addition of Hansa Biopharma to your portfolios can decrease your overall portfolio volatility.